Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06309953 · ClinicalTrials.gov registry record · Phase 4

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

A Phase 4 study, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
Phase 4
Development phase
99
Enrollment target

NCT06309953 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 99 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06309953, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
Phase 4
Development phase
99 participants
Enrollment target

Study Summary

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Interventions

  • DRUG Miebo

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2024-02-28
Est. Completion 2024-06-17
Phase Phase 4

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT06309953

The ClinicalTrials.gov registry entry for NCT06309953 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Miebo is the first listed.

NCT06309953 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06309953 about?

NCT06309953 is a clinical study titled "A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease". An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

What is the current status of trial NCT06309953?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 99 participants. The study started on 2024-02-28. Estimated completion is 2024-06-17.

What interventions are being tested in trial NCT06309953?

The interventions under investigation include: Miebo (DRUG).

Who is sponsoring clinical trial NCT06309953?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.